Anthrax Vaccine Contract for $78.4 Awarded by HHS
A biodefense company PharmAthene, Inc., specializing in the development and commercialization of medical countermeasures against chemical and biological threats, has been awarded additional contract for $78.4 by Department of Health and Human Services (HHS) to develop a second generation recombinant protective antigen (rPA) anthrax vaccine targeted for future procurement in the U.S. Strategic National [...]
Pneumococcal Disease Vaccine Approved by FDA
Prevnar 13, a pneumococcal 13-valent conjugate vaccine for infants and young children ages 6 weeks through 5 years, has been approved by FDA. The new vaccine extends the protection to six additional types of the disease causing bacteria. Prevnar 13 is the successor to Prevnar, the pneumococcal 7-valent conjugate vaccine licensed by the FDA in [...]
Gates Foundation Will Commit $10 Billion for Vaccine Development
Gates Foundation announced commitment of $10 billion over the next decade to help research, develop and deliver vaccines for the world’s poorest countries. The foundation used a model developed by a consortium led by the Institute of International Programs at the Johns Hopkins Bloomberg School of Public Health to project the potential impact of vaccines [...]
